Opportunities and challenges in using studies without a control group in comparative effectiveness reviews.

about

Opportunities and challenges in using studies without a control group in comparative effectiveness reviews.

Item

http://www.wikidata.org/entity/Q38520010

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Opportunities and challenges i ...... arative effectiveness reviews.

@en

type

Item

label

Opportunities and challenges i ...... arative effectiveness reviews.

@en

prefLabel

Opportunities and challenges i ...... arative effectiveness reviews.

@en

P1476

Opportunities and challenges i ...... arative effectiveness reviews.

@en

P2093

Esther E Avendano

http://www.w3.org/2001/XMLSchema#string

Ethan M Balk

http://www.w3.org/2001/XMLSchema#string

Issa J Dahabreh

http://www.w3.org/2001/XMLSchema#string

Jessica K Paulus

http://www.w3.org/2001/XMLSchema#string

Joseph Lau

http://www.w3.org/2001/XMLSchema#string

Stanley Ip

http://www.w3.org/2001/XMLSchema#string

P2860

When are randomised trials unnecessary? Picking signal from noise

The paired availability design for historical controls

Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography

Evaluating non-randomised intervention studies

Evidence in upheaval: incorporating observational data into clinical practice.

Comparison of evidence of treatment effects in randomized and nonrandomized studies.

Setting the bar in phase II trials: the use of historical data for determining "go/no go" decision for definitive phase III testing.

P304

152-161

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JRSM.1101

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-10-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26052654

http://www.w3.org/2001/XMLSchema#string